Word: hoechst
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...Food and Drug Administration might be reluctant to green-light the drug. That's because the FDA's pressure prompted Hoechst-Marion-Roussel to pull probucol from the market two years ago: The drug lowers the body's levels of artery-protecting "good" cholesterol by 40 percent, a definite drawback...
PARIS: Bowing to boycott threats from American anti-abortion groups, European pharmaceutical giant Hoechst transferred non-U.S. patent rights to the abortion pill RU-486 to one of the doctors who invented it. Although Edouard Sakiz, who headed Roussel Uclaf, the company that lead the development of RU-486 before it was acquired by Hoechst, will market the drug worldwide through a new company, he said he will not do business in the U.S. Once the drug wins approval, it will be distributed by The Population Council, a New York-based non-profit that received the U.S. patent from...
...case, the political debate will certainly make it more difficult to find an American company willing to distribute the drug. After the pill appeared in France, opponents sent 1.5 million critical postcards to Hoechst's U.S. subsidiary, Hoechst Celanese, and they will inevitably call a boycott against all products of any company that gets into the RU 486 business. And that's just the first volley. "Do you think the pharmaceutical corporate executive wants someone picketing in his neighborhood?" asks the Rev. Patrick Mahoney, spokesman for Operation Rescue...
Those political barriers, however, are quickly crumbling. Two days after his Inauguration, President Clinton ordered his Administration to "promote the testing, licensing and manufacturing" of RU 486. Until then, the French manufacturer of the drug, Roussel Uclaf, and its German parent company, Hoechst AG, had steadfastly shied away from becoming involved in the American market for fear of infuriating antiabortion activists. But in April, at the instigation of the U.S. Food and Drug Administration, Roussel announced a compromise: it agreed to license RU 486 to the U.S. Population Council, a nonprofit organization based in New York City, which in turn...
...abortion business. "Searle has never willingly made ((Cytotec)) available for use in abortion," a company official wrote in a letter to the Wall Street Journal in February. "It is not Searle's intention or desire to become embroiled in the abortion issue." Searle's reservations echo that of Hoechst president Wolfgang Hilger, who has been open about his ethical objections...